By Life Sciences Report : Rapid growth in the medical device industry and changes in the regulatory environment have propelled valuations in the medtech sector to the high end of the range. But new technologies create new investment opportunities. In this interview with The Life Sciences Report ,
Cytori Therapeutics ( CYTX -1.2% ) appoints Tiago Girao as VP of Finance and CFO effective September 2, 2014. He joins the firm from NuVasive where he was International Controller. Post your comment!
By Andy Batts : NuVasive 's (NASDAQ: NUVA ) bid to escape a $30 ..... negative catalyst for NuVasive 's stock, but I feel ..... it, especially after NUVA posted excellent second ..... 2010, it was found that NuVasive infringed the NeuroVision
NuVasive 's fortunes are bound to spinal fusion.
NuVasive ( NUVA ): Q1 EPS of $0.26 beats by $0.04 . Revenue of $159.5M (+5.2% Y/Y) beats by $2.06M . ( PR ) Post your comment!
treatment. Additionally, smaller competitors such as NuVasive NUVA have introduced new biologic products that compete with ..... be bundled with its hardware and instrument systems, NuVasive has been able to attract more spinal surgeons to embrace
We are no longer providing equity research on NuVasive NUVA . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
NuVasive NUVA announced its intentions to issue $325 ..... issue. In terms of valuation, we think NuVasive shares are about fairly valued, so we ..... a potential credit-sensitive play at NuVasive . We've seen 10-year issues of BBB
NuVasive NUVA reported fourth-quarter earnings that ..... commercial insurers still provide coverage for NuVasive 's lateral procedure though, after deeming ..... and long-term assumptions. We think NuVasive will have to largely generate growth in
We are placing NuVasive NUVA under review as we update our valuation. As we noted previously, we will moderately cut our fair value estimate due to a decrease